Effect of Secukinumab on Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: a Post hoc Analysis of the SUPREME Study

COMMENTED

Psoriasis

Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study

Br J Dermatol.

Papini M, Cusano F, Romanelli M, Burlando M, Stinco G, Girolomoni G, Peris K, Potenza C, Offidani A, Bartezaghi M, Aloisi E, Costanzo A, SUPREME study group

doi: 10.1111/bjd.18013.

Psoriasis

Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post-hoc analysis of the BRIDGE study

J Eur Acad Dermatol Venereol.

Van de Kerkhof PCM, Loewe R, Mrowietz U, Falques M, Pau-Charles I, Szepietowski JC

doi: 10.1111/jdv.15922.

Psoriasis

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study

J Am Acad Dermatol.

Bagel J, Duffin KC, Moore A, Ferris LK, Siu K, Steadman J, Kianifard F, Nyirady J, Lebwohl M

doi: 10.1016/j.jaad.2017.05.033.

Psoriasis

Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study

J Eur Acad Dermatol Venereol.

Thaçi D, Körber A, von Kiedrowski R, Bachhuber T, Melzer N, Kasparek T, Duetting E, Kraehn-Senftleben G, Amon U, Augustin M

doi: 10.1111/jdv.15962.

Psoriasis

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)

J Am Acad Dermatol.

Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, Goyal K, Lawson F, Langholff W, Hopkins L, Fakharzadeh S, Srivastava B, Menter A

doi: 10.1016/j.jaad.2017.08.051.

AcnePsoriasis

Efficacy of secukinumab and adalimumab in psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis: Results from the EXCEED, a randomised, double-blind head-to-head monotherapy study

Br J Dermatol

Gottlieb AB, Merola JF, Reich K, Behrens F, Nash P, Griffiths CEM, Bao W, Pellet P, Pricop L, McInnes IB

doi: 10.1111/bjd.20413

Psoriasis

Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post-hoc analysis through 64 weeks from reSURFACE 1 trial

J Eur Acad Dermatol Venereol

Warren RB, Carrascosa JM, Fumero E, Schoenenberger A, Lebwohl MG, Szepietowski JC, Reich K

doi: 10.1111/jdv.16964

PsoriasisPsoriatic Arthritis

Secukinumab Demonstrates High Sustained Efficacy and a Favorable Safety Profile in Patients with Moderate to Severe Psoriasis through 5 Years of Treatment (SCULPTURE Extension Study)

J Eur Acad Dermatol Venereol.

Bissonnette R, Luger T, Thaçi D, Toth D, Lacombe A, Xia S, Mazur R, Patekar M, Charef P, Milutinovic M, Leonardi C, Mrowietz U

doi: 10.1111/jdv.14878.

Psoriasis

Efficacy of ixekizumab on nail psoriasis in pediatric patients with moderate-to-severe psoriasis: a post-hoc analysis from IXORA-PEDS

J Eur Acad Dermatol Venereol

Seyger MMB, Reich A, El Baou C, Schuster C, Riedl E, Paller AS

doi: 10.1111/jdv.17564

Related content

Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study

Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post-hoc analysis of the BRIDGE study

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study

Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Efficacy of secukinumab and adalimumab in psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis: Results from the EXCEED, a randomised, double-blind head-to-head monotherapy study

Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post-hoc analysis through 64 weeks from reSURFACE 1 trial

Secukinumab Demonstrates High Sustained Efficacy and a Favorable Safety Profile in Patients with Moderate to Severe Psoriasis through 5 Years of Treatment (SCULPTURE Extension Study)

Efficacy of ixekizumab on nail psoriasis in pediatric patients with moderate-to-severe psoriasis: a post-hoc analysis from IXORA-PEDS